The main iron chelator used for transfusional iron overload is desferrioxamine, which is expensive, has toxic side effects, and has to be given subcutaneously. An orally active iron chelator is therefore required. The effects of oral 1,2-dimethyl-3-hydroxypyrid-4-one on urinary iron excretion were studied in eight patients who had received multiple transfusions: four had myelodysplasia and four P thalassaemia major. Different daily doses of the drug up to 100 mg/kg/day, alone or in combination with ascorbic acid, were used. In three patients with thalassaemia the effect of the drug was compared with that of subcutaneous desferrioxamine at the same daily dose. In all eight patients a single dose of oral 1,2-dimethyl-3-hydroxypyrid-4-one resulted in substantial urinary iron excretion, mainly in the first 12 hours. Urinary iron excretion increased with the dose and with the degree of iron loading of the patient. Giving two or three divided doses over 24 hours resulted in higher urinary iron excretion than a single dose of the same amount over the same time. In most patients coadministration of oral ascorbic acid further increased urinary iron excretion. 1,2-Dimethyl-3-hydroxypyrid-4-one caused similar iron excretion to that achieved with subcutaneous desferrioxamine at a comparable dose. In some cases the iron excretion was sufficiently high (maximum 99 mg/day) to suggest that a negative iron balance could be easily achieved with these protocols in patients receiving regular transfusions. No evidence of toxicity was observed on thorough
Introduction
Subcutaneous desferrioxamine has been the main iron chelator used to treat transfusional iron overload since it was introduced 10 years ago. I 2 Its use is limited to a small proportion of the patients affected world wide because it is expensive and orally inactive. Oliviery et al also showed toxic side effects at high doses or when iron stores were low.3 Desferrioxamine given orally4 or as a suppository' has limited success in increasing iron excretion, so a cheap, orally active, non-toxic iron chelator is needed.
Some other chelators have been tested in man but with little success. One of these, 2,3-dihydroxybenzoic acid, was initially found to be effective but was later abandoned. Another chelator, rhodotorulic acid,7 was found to be painful when injected parenterally, and another, cholyihydroxamic acid,8 causes transient diarrhoea. Finally, subcutaneous diethylenetriaminepenta-acetic acid increases iron excretion but also removes other trace metals such as zinc. 9 No follow up studies have been reported for these drugs, but several other experimental chelators that increase iron excretion in animals also have potential for clinical use. These include 2,4-dihydroxypyridine-N-oxide,"°the pyridoxal isonicotinoylhydrazones," spermidine catecholates," deferrithiocins," and phenolic ethylenediamines."4
The most promising orally active experimental chelators are the 1,2-dialkyl-3-hydroxypyrid-4-ones,"' which can be easily and cheaply synthesised from the natural plant product maltol or its homologue ethyl maltol and the related alkylamine in a one step reaction. '6 These chelators form strong complexes with iron in the ratio of three to one at physiological pH"; and they mobilise iron in 12 DECEMBER 1987 vitro from transferrin,'8 lactoferrin,'9 ferritin,20 and haemosiderin2' and in vivo after parenteral or intragastric administration in mice22 and rabbits,23 the effect being similar to or greater than that of parenteral desferrioxamine.
In a preliminary study of three patients with myelodysplasia we showed that 1,2-dimethyl-3-hydroxypyrid-4-one is an orally active iron chelator in man. 24 Increased urinary iron excretion occurred within the first 12 hours after its administration; urinary excretion of zinc, calcium, and magnesium was not affected. We now report a more extensive study in eight patients with myelodysplasia or thalassaemia given single or repeated doses of oral 1,2-dimethyl-3-hydroxypyrid-4-one, alone or in combination with ascorbic acid; in three patients with thalassaemia the urinary iron excretion caused by the drug with and without ascorbic acid was compared with that caused by subcutaneous desferrioxamine with ascorbic acid.
Patients and methods
Approval for the trial on both groups of patients was obtained from the ethical committee of the Royal Free Hospital and the Department of Health and Social Security; all eight patients gave their written consent. Table I summarises relevant clinical histories of the patients. All the patients were loaded with iron, and in general the patients with thalassaemia were more heavily loaded. Iron loading was determined by the number of units of red cells transfused and serum ferritin concentrations. The four patients with myelodysplasia had not received regular chelation with desferrioxamine. Three patients (cases 6, 7, and 8) with thalassaemia had received subcutaneous desferrioxamine since 1978, 1979 , and 1980, respectively, but were poor compliers. The remaining patient with thalassaemia (case 5) had received desferrioxamine between 1979 and 1983 but had then stopped chelation treatment. Haemoglobin concentrations were above 90 g/l in all eight patients at the time of the study.
1,2-Dimethyl-3-hydroxypyrid-4-one, prepared as previously described '6 and over 99 -5% pure, was taken as 500 mg 
Results
Urinary iron excretion increased in all the patients after the administration of 1,2-dimethyl-3-hydroxypyrid4-one by mouth and desferrioxamine with ascorbic acid subcutaneously (table II). The amount of iron excreted was generally higher in the patients with thalassaemia (cases [5] [6] [7] [8] [3] [4] [5] ; in two other patients with thalassaemia ascorbic acid was associated with increased iron excretion in one (case 7) but not in the other (case 8). When 1,2-dimethyl-3-hydroxypyrid-4-one with and without ascorbic acid was compared with similar doses of desferrioxamine and ascorbic acid in two patients with thalassaemia urinary iron excretion was about the same for the three treatments in one patient (case 8) but in another patient (case 7) it was much higher with 1,2-dimethyl-3-hydroxypyrid4-one and ascorbic acid. In the remaining patient with thalassaemia urinary iron excretion was about the same when 2 g or 3 g doses of the chelators were administered, but it was much higher when two infusions ofdesferrioxamine (each of 2 g) and ascorbic acid were given in comparison with two 2 g doses of 1,2-dimethyl-3-hydroxypyrid-4-one (table II; days 4, 5, and 6). Daily urinary iron excretion in all the patients with thalassaemia after 1,2-dimethyl-3-hydroxypyrid-4-one with and without ascorbic acid was in most cases over 25 mg, which is the estimated minimum daily intake of iron from transfusions.
Serum concentrations of zinc, copper, calcium, and magnesium before and after the administration of the chelators varied slightly in each patient, but there was no consistent increase or decrease when all the patients' data were compared (table III) . Slight variations were also observed in white cell and platelet counts, serum liver enzyme activities, and urea concentrations before and after treatment with 1,2-dimethyl-3-hydroxypyrid-4-one, but these were inconsistent (table III) .
Discussion
In these studies, which aimed at determining a safe and effective oral dose of 1,2-dimethyl-3-hydroxypyrid-4-one for the treatment of transfusional iron overload, we explored different protocols of administration in eight patients. Oral 1,2-dimethyl-3-hydroxypyrid-4-one consistently increased urinary iron excretion in all the patients. For a given dose (mg/kg) of 1,2-dimethyl-3-hydroxypyrid-4-one excretion of iron was, however, higher in the patients with thalassaemia (cases 5-8), who were more iron loaded (based on units of blood transfused and serum ferritin concentration), than in the patients with myelodysplasia (cases 1-4). Although urinary iron excretion varies with the concentration of haemoglobin at which the patient is tested,25 this could not explain the differences we found as both groups of patients were tested at comparable haemoglobin concentrations.
In almost all the patients increasing the size of a single dose or using repeated daily doses26 resulted in substantially higher total urinary iron excretion than smaller single oral doses. With these protocols the maximum daily urinary iron excretion was probably not reached in any of the patients. Higher daily doses, given singly or in divided doses, clearly could result in even higher urinary iron excretion.
Giving oral 1,2-dimethyl-3-hydroxypyrid-4-one with ascorbic acid caused further increases in urinary iron excretion in most but not all cases. The findings are similar to those with desferrioxamine, and despite the absence ofa uniform response with ascorbic acid this vitamin, at least in a small dose (200 mg), may be useful in combination with oral 1,2-dimethyl-3-hydroxypyrid-4-one, in a similar manner to that used with desferrioxamine.
Oral 1,2-dimethyl-3-hydroxypyrid-4-onewithorwithoutascorbic acid seemed to be of equivalent potency in increasing urinary iron excretion to subcutaneous desferrioxamine with ascorbic acid. Similar results were previously obtained when these chelators were compared in animals2226 and in one patient with myelodysplasia. 24 We emphasise, however, that, although'desferrioxamine treatment is limited by the need for slow parenteral administration, treatment with oral 1,2-dimethyl-3-hydroxypyrid-4-one could be more effective because it can be conveniently administered several times a day. Studies of higher doses of 1,2-dimethyl-3-hydroxypyrid-4-one over prolonged periods, however, are needed to establish its maximum and long term effectiveness and the presence of possible toxic side effects. The apparent lack of toxicity of oral 1,2-dimethyl-3-hydroxypyrid-4-one (table III) and its tolerance by all the patients, particularly the patient who received 38 g in two weeks (case 4), is encouraging.
In mice 1,2-dimethyl-3-hydroxypyrid-4-one seemed not to be toxic when given daily at a dose of 300 mg/kg for a month and twice daily (2x300 mg/kg) for two weeks. 26 The median lethal intraperitoneal dose is about 1 g/kg in mice22 and 600-700 mg/kg in rats'6; the median lethal oral doses are much higher. The oral doses given in our patients were less than 100 mg/kg/day, which is much less than median lethal doses in animals. Rabbits, for example, have shown no toxicity at doses of 200 mg/kg/day. 23 The main aim of this study was to establish whether a non-toxic tolerable dose of oral 1,2-dimethyl-3-hydroxypyrid-4-one could achieve negative iron balance in patients loaded with iron, particularly those with , thalassaemia major. Using protocols of progressive dose increases, repeated administration, and coadministration with ascorbic acid, we successfully increased urinary iron excretion above 25-33 mg/day, which is the estimated daily net iron intake from transfusions in these patients, without observing any toxicity. In some cases the maximum urinary iron excretion caused by oral 1,2-dimethyl-3-hydroxypyrid-4-one with or without ascorbate was much higher than that caused by desferrioxamine, and in one patient (case 8) it reached 99 mg, which is about a quarter ofthe binding capacity of 3 g 1,2-dimethyl-3-hydroxypyrid-4-one. This indicates that a large proportion of the administered dose of 1,2-dimethyl-3-hydroxypyrid4-one is absorbed efficiently from the gastrointestinal tract, mobilises iron from the accessible iron pool(s), and is then excreted as the iron complex in urine.24 27 28 Total iron excretion may have been even higher because the faecal iron excretion caused by 1,2-dimethyl-3-hydroxypyrid-4-one was not measured. Full metabolic studies are now needed to assess the total efficacy of this chelator in excretion of iron.
In conclusion, oral 1,2-dimethyl-3-hydroxypyrid-4-one is a highly effective iron chelator in man without obvious toxicity short term. It can achieve negative iron balance when administered at doses similar to those of desferrioxamine and in combination with ascorbic acid. As it can be easily and cheaply prepared from the natural product maltol"6 there is clearly a need for its speedy development, including full toxicological studies, and for more extensive and prolonged trials in patients receiving multiple transfusion. 1,2-Dimethyl-3-hydroxypyrid-4-one or another effective a ketohydroxy chelator29 could be used in other diseases of iron or other metal imbalance or toxicity. 
ONE HUNDRED YEARS AGO
The Moniteur Belge has published the text of an important report by the Belgian Minister of the Interior, and of two decrees of the King, which have for their object the improvement of the sanitary regulation of factories and workshops in Belgium. In that country the supreme control ofmost sanitary matters, such as the adulteration offood and the condition ofthe dwellings of the poor, is at present vested in the communal authorities, and the system seems to be in need of reform in many important respects. But in the control ofdangerous and unhealthy factoriesand workshops the Central Government has some voice, and the need of reform in this control, as shown by the inquiries of the Commission on Labour, has called forth the recent Royal decrees.
The first of these decrees provides, amongst other things, that future applications for permission to carry on one ofthe establishments ofthis latter class must be accompanied by detailed information as to the measures proposed, in the interests of the work-people, for counteracting the dangers attaching to the particular business, and also by a special report, prepared by an official or a competent technical commission on those measures. The authorisation to be granted by the Central Government is to prescribe specifically the measures which that special report shows to be essential. The managers ofeach authorised factory are, further, to make an annual report to the Minister of the Interior, showing the approximate number of hands employed, their age and sex, the duration oftheir daily labour, the amount of rest during each day and each week; the means of warming, lighting, and ventilating the workrooms; the rules of cleanliness observed in the workshops and by the workers; the amount of air-space for each person; the arrangements for medical assistance in cases of accident; the precautions taken against explosions and fire, against the escape of steam, gas, and dust, and against accidents from machinery; and the measures for ensuring generally good sanitary arrangements in the workshops, as regards the alternation of work, the meals, the bath-rooms, the closets, etc. The Government reserves power to impose any fresh restrictions that may from time to time appear necessary.
In the circular letter, in which the Minister of the Interior draws the attention of the provincial governors to this decree, the great need that exists for the improvement aimed at is set out, and the Minister further incidentally refers to the fact that boys under twelve years and girls under fourteen years of age are prohibited from working in mines, and points out that a similar restriction should be attached to the more dangerous and unhealthy occupations now being dealt with.
The second of the Royal decrees has for its object the improvement of the medical supervision ofunhealthy and dangerous factories. The Corresponding Members of the Medical Provincial Commission are to be augmented, and are to be appointed in all towns and communes where their presence may be deemed to be useful. They are to be nominated by the King for a term of six years, on the proposal of the governors, and with the approval of the provincial medical authorities. They are to supply all information required of them by the Medical Commission, and at the end of each year they are to draw up a report on the matters deserving attention. Hitherto these Correspondents have been obliged to be members ofthe medical profession, but in future the post may be held by apothecaries, veterinary surgeons, burgomasters, communal secretaries, schoolmasters, journalists, engineers, or architects. The Minister of the Interior hopes that the opportunity of obtaining the title of "Correspondent" will encourage many persons to cooperate in the work of sanitary reform in the country.
(British MedicalJournal 1887;i: 1224.)
